Prospective Korean Marginal Zone Lymphomas Cohort Study: Initial Data Analysis of 407 Cases
Year: 2023
Type: conference-abstract
Abstract: Background: Marginal zone lymphoma (MZL) is a distinct subgroup of non-Hodgkin’s lymphoma (NHL), which is typically characterized by an indolent clinical course and long survival duration. In Korea, MZL accounts for 21% of all B-cell lymphoma and is the second most frequent histologic subtype following diffuse large B-cell lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observations including clinical presentation, evaluation patters, treatment modality, results, and side effects. Methods: Histological newly diagnosed patients with MZL were eligible. We received official approval from each study site their local IRB. All patients gave written informed consent prior to study participation. Patients’ data was collected via e-CRF on the Web. Results: In total, 407 patients were enrolled (median age: 56 years, range: 20–86 years) between July 2010 and September 2019 from twenties hospitals of the Consortium for Improving Survival of Lymphoma (CISL). Male-to-female ratio was about 1.2 to 1 (219 vs. 188). Nodal MZLs were observed in 48 patients (11.8%). Almost of registered MZL patients was MZL of MALT type 359 (88.2%). The most common site of involvement was orbit and ocular adnexa (29.7%) followed by stomach (17%), multiple MALT sites involved (15.7%), and lung (5.4%). Ninety-four percent (384) of the patients initially presented with Ann Arbor stage I/II. BM involvement was detected in 7.3% (28 of 384). Bulky mass and B symptom was observed in only 3 patients, respectively. 71% of the patients (290 of 407) and 36 patients (8.8%) were categorized as the low and low-intermediate risk group according to the IPI, respectively. Initial treatment was conducted by Patients’ disease status; ten percentage of patients were observed without treatment. Chemotherapy alone 106 (26%), RT alone 80 (19.7%), Surgery + Chemotherapy 46 (11.3%), H. pylori eradication 35 (8.6%), Surgery alone 26 (6.4%). 5 years PFS and OS duration were 89.4% (32 events) and 97.3 (11 events). Eleven cases of hepatitis reactivation were observed during treatment. Conclusion: This is a first large scale prospective MZL cohort study in Korea. The results showed that the characteristics of MZL that survives for a long time and causes frequent recurrence were well represented. However, for accurate characteristic analysis, it is necessary to collect continuous survival-related data for the next five years or more. This study will replacing 207 retrospective studies published in 2004 and can be used as basic data to determine survival changes after Rituximab is used (ClinicalTrials.gov ID: NCT02732236). The research was funded by: The research was funded by JW pharmaceutical. Keyword: indolent non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract.
Source: Hematological Oncology
DOI: 10.1002/hon.3165_537
Authors: S.Y. OH, Y. Park, S. Lim, J. Jo, B. S. Sohn, S. J. Kim, W. S. Kim, H. J. Kim, J. H. Won, K. S. Jung, M. H. Chang, H. Eom, H. Sung, H. S. Lee, Y. R. Do, H. J. Kang, H. Yhim, B. Park, J. H. Lee, J. H. Lee, W. S. Lee, S. H. Jeong, D. H. Yoon, C. Suh
Institutions: Dong-A University Hospital, Korea University Anam Hospital, Inje University Haeundae Paik Hospital, Ulsan University Hospital, Inje University Sanggye Paik Hospital, Samsung Medical Center, Hallym University Sacred Heart Hospital, Soonchunhyang University, Pusan National University Yangsan Hospital, National Health Insurance Service Ilsan Hospital, National Cancer Center, Korea University Ansan Hospital, Kosin University Gospel Hospital, Keimyung University Dongsan Medical Center, Korea Institute of Radiological and Medical Sciences, Jeonbuk National University Hospital, Hanyang University, Gachon University Gil Medical Center, Inje University Busan Paik Hospital, Ajou University, Asan Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4380079314